{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:05:31Z","timestamp":1787069131665,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Zielsetzung<\/jats:title>\n                    <jats:p>Mithilfe von Abrechnungsdaten wird die Verordnungsh\u00e4ufigkeit von Analgetika bei Patienten mit Diagnose einer rheumatoiden Arthritis (RA), axialen Spondyloarthritis (axSpA), Psoriasisarthritis (PsA) bzw. eines systemischen Lupus erythematodes (SLE) im Jahr 2019 untersucht.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>Eingeschlossen wurden Versicherte der Barmer \u2265\u202f18\u00a0Jahre im Jahr 2019 mit Diagnose einer RA (M05, M06), axSpA (M45), PsA (M07.0\u20133) oder eines SLE (M32.1, 8, 9). Analgetika wurden \u00fcber die ATC(Anatomisch-Therapeutisch-Chemisches Klassifikationssystem)-Codes identifiziert. Berichtet wird der Anteil an Personen mit \u2265\u202f1\u00a0Analgetikaverordnung f\u00fcr die jeweiligen Krankheitsbilder im Jahr 2019 sowie f\u00fcr Opioide altersstandardisiert in jedem der Jahre 2005 bis 2019. Zus\u00e4tzlich wird der Anteil an Opioidlangzeitverordnungen (Rezepte in \u2265\u202f3\u00a0aufeinanderfolgenden Quartalen) im Jahr 2006 und 2019 verglichen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Metamizol (29\u201333\u202f%) war das am h\u00e4ufigsten verordnete Analgetikum. NSAR(nichtsteroidale Antirheumatika)\/Coxibe wurden zu 35\u202f% (SLE) bis 50\u202f% (axSpA) verordnet; 11\u201313\u202f% der Versicherten wurden schwach wirksame und 6\u20138\u202f% stark wirksame Opioide verordnet. Von 2005 bis 2019 blieb der Anteil an Personen mit \u2265\u202f1\u00a0Opioidverordnung stabil bei gleichbleibend bzw. leicht r\u00fcckl\u00e4ufiger Verordnung schwach wirksamer Opioide und h\u00e4ufigerer Verordnung stark wirksamer Opioide. Der Anteil an Langzeitopioidverordnungen stieg von 2006 bis 2019 von 8,9\u202f% auf 11,0\u202f% (RA), von 6,9\u202f% auf 9,1\u202f% (axSpA), von 7,8\u202f% auf 9,5\u202f% (PsA) und von 7,5\u202f% auf 8,8\u202f% (SLE), entsprechend einer Zunahme um 17\u201324\u202f%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die Verordnung von Opioiden bei Versicherten mit entz\u00fcndlich rheumatischen Diagnosen ist in Deutschland nicht so hoch wie in anderen L\u00e4ndern, allerdings ist der Anteil an Langzeitverordnungen deutlich angestiegen. Auff\u00e4llig ist die h\u00e4ufige Verordnung von Metamizol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-021-00971-y","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T08:03:15Z","timestamp":1617782595000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prescription of analgesics in patients with rheumatic diseases in Germany","Verordnung von Schmerzmitteln bei Patienten mit rheumatischen Erkrankungen in Deutschland"],"prefix":"10.1007","volume":"80","author":[{"given":"K.","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Callhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"1","key":"971_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00393-016-0156-5","volume":"76","author":"K Albrecht","year":"2017","unstructured":"Albrecht\u00a0K, Huscher\u00a0D, Eidner\u00a0T, Kleinert\u00a0S, Spathling-Mestekemper\u00a0S, Bischoff\u00a0S, Zink\u00a0A (2017) Medical treatment of rheumatoid arthritis in 2014: current data from the German collaborative arthritis centers. Z\u00a0Rheumatol 76(1):50\u201357. https:\/\/doi.org\/10.1007\/s00393-016-0156-5","journal-title":"Z Rheumatol"},{"issue":"2","key":"971_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht\u00a0K, Luque Ramos\u00a0A, Callhoff\u00a0J, Hoffmann\u00a0F, Minden\u00a0K, Zink\u00a0A (2018) Outpatient care and disease burden of rheumatoid arthritis : results of a\u00a0linkage of claims data and a\u00a0survey of insured persons. Z\u00a0Rheumatol 77(2):102\u2013112. https:\/\/doi.org\/10.1007\/s00393-017-0294-4","journal-title":"Z Rheumatol"},{"issue":"1","key":"971_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00393-020-00775-6","volume":"79","author":"M Schneider","year":"2020","unstructured":"Schneider\u00a0M, Baseler\u00a0G, Funken\u00a0O, Heberger\u00a0S, Kiltz\u00a0U, Klose\u00a0P, Kruger\u00a0K, Langhorst\u00a0J, Mau\u00a0W, Oltman\u00a0R, Richter\u00a0B, Seitz\u00a0S, Sewerin\u00a0P, Tholen\u00a0R, Weseloh\u00a0C, Witthoft\u00a0M, Specker\u00a0C (2020) Management of early rheumatoid arthritis : interdisciplinary guideline. Z\u00a0Rheumatol 79(1):1\u201338. https:\/\/doi.org\/10.1007\/s00393-020-00775-6","journal-title":"Z Rheumatol"},{"issue":"1","key":"971_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00393-019-00707-z","volume":"79","author":"U Kiltz","year":"2020","unstructured":"Kiltz\u00a0U, Braun\u00a0J (2020) Current treatment of axial spondylarthritis : clinical efficacy. Z\u00a0Rheumatol 79(1):13\u201322. https:\/\/doi.org\/10.1007\/s00393-019-00707-z","journal-title":"Z Rheumatol"},{"issue":"2","key":"971_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41584-019-0360-1","volume":"16","author":"SC Kim","year":"2020","unstructured":"Kim\u00a0SC, Solomon\u00a0DH (2020) Towards defining the safer use of opioids in rheumatology. Nat Rev Rheumatol 16(2):71\u201372. https:\/\/doi.org\/10.1038\/s41584-019-0360-1","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"971_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3899\/jrheum.180668","volume":"46","author":"A Luque Ramos","year":"2019","unstructured":"Luque Ramos\u00a0A, Redeker\u00a0I, Hoffmann\u00a0F, Callhoff\u00a0J, Zink\u00a0A, Albrecht\u00a0K (2019) Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J\u00a0Rheumatol 46(6):564\u2013571. https:\/\/doi.org\/10.3899\/jrheum.180668","journal-title":"J Rheumatol"},{"key":"971_CR7","unstructured":"Gelbe Liste (2018) WHO-Stufenplan. https:\/\/www.gelbe-liste.de\/schmerztherapie\/schmerztherapie-who-stufenplan. Zugegriffen: 9. Sept. 2020"},{"key":"971_CR8","doi-asserted-by":"publisher","unstructured":"Pace MLG, Glickman M, Grande E, Zupanic T, Wojtyniak B et\u00a0al (2013) Revision of the European standard population report of Eurostat\u2019s task force. Eurostat, European Union. https:\/\/ec.europa.eu\/eurostat\/web\/products-manuals-and-guidelines\/-\/KS-RA-13-028. Zugegriffen: 22. Sept. 2020. https:\/\/doi.org\/10.2785\/11470","DOI":"10.2785\/11470"},{"issue":"5","key":"971_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ejp.802","volume":"20","author":"U Marschall","year":"2016","unstructured":"Marschall\u00a0U, L\u2019Hoest\u00a0H, Radbruch\u00a0L, Hauser\u00a0W (2016) Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain 20(5):767\u2013776. https:\/\/doi.org\/10.1002\/ejp.802","journal-title":"Eur J Pain"},{"issue":"3","key":"971_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00393-013-1244-4","volume":"73","author":"F Luttosch","year":"2014","unstructured":"Luttosch\u00a0F, Baerwald\u00a0C (2014) Pain management in elderly patients. Z\u00a0Rheumatol 73(3):233\u2013243. https:\/\/doi.org\/10.1007\/s00393-013-1244-4","journal-title":"Z Rheumatol"},{"issue":"3","key":"971_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00482-015-0003-7","volume":"29","author":"J Schulze","year":"2015","unstructured":"Schulze\u00a0J, Freitag\u00a0MH, Glaeske\u00a0G, Schmiemann\u00a0G, Hoffmann\u00a0F (2015) Pain medication in nursing home residents with and without cancer. Most frequently with metamizole. Schmerz 29(3):276\u2013284. https:\/\/doi.org\/10.1007\/s00482-015-0003-7","journal-title":"Schmerz"},{"key":"971_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2318-14-20","volume":"14","author":"F Hoffmann","year":"2014","unstructured":"Hoffmann\u00a0F, van den Bussche\u00a0H, Wiese\u00a0B, Glaeske\u00a0G, Kaduszkiewicz\u00a0H (2014) Diagnoses indicating pain and analgesic drug prescription in patients with dementia: a\u00a0comparison to age- and sex-matched controls. BMC Geriatr 14:20. https:\/\/doi.org\/10.1186\/1471-2318-14-20","journal-title":"BMC Geriatr"},{"issue":"5","key":"971_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/art.40789","volume":"71","author":"YC Lee","year":"2019","unstructured":"Lee\u00a0YC, Kremer\u00a0J, Guan\u00a0H, Greenberg\u00a0J, Solomon\u00a0DH (2019) Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheumatol 71(5):670\u2013677. https:\/\/doi.org\/10.1002\/art.40789","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"971_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10067-016-3239-4","volume":"35","author":"JA Zamora-Legoff","year":"2016","unstructured":"Zamora-Legoff\u00a0JA, Achenbach\u00a0SJ, Crowson\u00a0CS, Krause\u00a0ML, Davis\u00a0JM 3rd, Matteson\u00a0EL (2016) Opioid use in patients with rheumatoid arthritis 2005\u20132014: a\u00a0population-based comparative study. Clin Rheumatol 35(5):1137\u20131144. https:\/\/doi.org\/10.1007\/s10067-016-3239-4","journal-title":"Clin Rheumatol"},{"issue":"9","key":"971_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/art.40152","volume":"69","author":"JR Curtis","year":"2017","unstructured":"Curtis\u00a0JR, Xie\u00a0F, Smith\u00a0C, Saag\u00a0KG, Chen\u00a0L, Beukelman\u00a0T, Mannion\u00a0M, Yun\u00a0H, Kertesz\u00a0S (2017) Changing trends in opioid use among patients with rheumatoid arthritis in the United States. Arthritis Rheumatol 69(9):1733\u20131740. https:\/\/doi.org\/10.1002\/art.40152","journal-title":"Arthritis Rheumatol"},{"key":"971_CR16","doi-asserted-by":"publisher","first-page":"3891436","DOI":"10.1155\/2020\/3891436","volume":"2020","author":"ME Machado-Duque","year":"2020","unstructured":"Machado-Duque\u00a0ME, Ramirez-Valencia\u00a0DM, Murillo-Munoz\u00a0MM, Machado-Alba\u00a0JE (2020) Trends in opioid use in a\u00a0cohort of patients with rheumatoid arthritis. Pain Res Manag 2020:3891436. https:\/\/doi.org\/10.1155\/2020\/3891436","journal-title":"Pain Res Manag"},{"issue":"2","key":"971_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2215-0366(18)30471-1","volume":"6","author":"HJ Curtis","year":"2019","unstructured":"Curtis\u00a0HJ, Croker\u00a0R, Walker\u00a0AJ, Richards\u00a0GC, Quinlan\u00a0J, Goldacre\u00a0B (2019) Opioid prescribing trends and geographical variation in England, 1998\u20132018: a\u00a0retrospective database study. Lancet Psychiatry 6(2):140\u2013150. https:\/\/doi.org\/10.1016\/S2215-0366(18)30471-1","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"971_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejp.1291","volume":"23","author":"C Chenaf","year":"2019","unstructured":"Chenaf\u00a0C, Kabore\u00a0JL, Delorme\u00a0J, Pereira\u00a0B, Mulliez\u00a0A, Zenut\u00a0M, Delage\u00a0N, Ardid\u00a0D, Eschalier\u00a0A, Authier\u00a0N (2019) Prescription opioid analgesic use in France: trends and impact on morbidity-mortality. Eur J Pain 23(1):124\u2013134. https:\/\/doi.org\/10.1002\/ejp.1291","journal-title":"Eur J Pain"},{"issue":"612","key":"971_CR19","first-page":"1262","volume":"14","author":"D Ruchat","year":"2018","unstructured":"Ruchat\u00a0D, Suter\u00a0MR, Rodondi\u00a0PY, Berna\u00a0C (2018) Opioid consumption from 1985 to 2015 : the situation in Switzerland, with an international comparison. Rev Med Suisse 14(612):1262\u20131266","journal-title":"Rev Med Suisse"},{"issue":"6","key":"971_CR20","doi-asserted-by":"publisher","first-page":"e019491","DOI":"10.1136\/bmjopen-2017-019491","volume":"8","author":"T Ashaye","year":"2018","unstructured":"Ashaye\u00a0T, Hounsome\u00a0N, Carnes\u00a0D, Taylor\u00a0SJC, Homer\u00a0K, Eldridge\u00a0S, Spencer\u00a0A, Rahman\u00a0A, Foell\u00a0J, Underwood\u00a0MR, Team\u00a0CS (2018) Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a\u00a0cohort analysis of the COPERS trial. BMJ Open 8(6):e19491. https:\/\/doi.org\/10.1136\/bmjopen-2017-019491","journal-title":"BMJ Open"},{"issue":"2","key":"971_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3899\/jrheum.170630","volume":"45","author":"JD Dau","year":"2018","unstructured":"Dau\u00a0JD, Lee\u00a0M, Ward\u00a0MM, Gensler\u00a0LS, Brown\u00a0MA, Learch\u00a0TJ, Diekman\u00a0LA, Tahanan\u00a0A, Rahbar\u00a0MH, Weisman\u00a0MH, Reveille\u00a0JD (2018) Opioid analgesic use in patients with ankylosing spondylitis: an analysis of the prospective study of outcomes in an ankylosing spondylitis cohort. J\u00a0Rheumatol 45(2):188\u2013194. https:\/\/doi.org\/10.3899\/jrheum.170630","journal-title":"J Rheumatol"},{"issue":"8","key":"971_CR22","doi-asserted-by":"publisher","first-page":"e0221153","DOI":"10.1371\/journal.pone.0221153","volume":"14","author":"B Rosner","year":"2019","unstructured":"Rosner\u00a0B, Neicun\u00a0J, Yang\u00a0JC, Roman-Urrestarazu\u00a0A (2019) Opioid prescription patterns in Germany and the global opioid epidemic: systematic review of available evidence. PLoS ONE 14(8):e221153. https:\/\/doi.org\/10.1371\/journal.pone.0221153","journal-title":"PLoS ONE"},{"issue":"2","key":"971_CR23","doi-asserted-by":"publisher","first-page":"e001029","DOI":"10.1136\/rmdopen-2019-001029","volume":"5","author":"AP Trouvin","year":"2019","unstructured":"Trouvin\u00a0AP, Berenbaum\u00a0F, Perrot\u00a0S (2019) The opioid epidemic: helping rheumatologists prevent a\u00a0crisis. RMD Open 5(2):e1029. https:\/\/doi.org\/10.1136\/rmdopen-2019-001029","journal-title":"RMD Open"},{"issue":"2","key":"971_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00393-015-1686-y","volume":"75","author":"M Krasselt","year":"2016","unstructured":"Krasselt\u00a0M, Hauser\u00a0W, Petzke\u00a0F, Baerwald\u00a0C (2016) S3 guidelines on long-term opioid treatment in non-cancer pain. Recommendations for opioid use in clinical rheumatology. Z\u00a0Rheumatol 75(2):128\u2013132. https:\/\/doi.org\/10.1007\/s00393-015-1686-y","journal-title":"Z Rheumatol"},{"issue":"1","key":"971_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00393-015-0018-6","volume":"75","author":"WW Bolten","year":"2016","unstructured":"Bolten\u00a0WW, Kruger\u00a0K, Reiter-Niesert\u00a0S, Stichtenoth\u00a0DO, Kommission Pharmakotherapie der DGRh (2016) DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain. Z\u00a0Rheumatol 75(1):103\u2013116. https:\/\/doi.org\/10.1007\/s00393-015-0018-6","journal-title":"Z Rheumatol"},{"issue":"6","key":"971_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00393-016-0148-5","volume":"75","author":"WW Bolten","year":"2016","unstructured":"Bolten\u00a0WW, Kruger\u00a0K (2016) Coxibs. Z\u00a0Rheumatol 75(6):595\u2013598. https:\/\/doi.org\/10.1007\/s00393-016-0148-5","journal-title":"Z Rheumatol"},{"issue":"7","key":"971_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/pds.4202","volume":"26","author":"K Jobski","year":"2017","unstructured":"Jobski\u00a0K, Luque Ramos\u00a0A, Albrecht\u00a0K, Hoffmann\u00a0F (2017) Pain, depressive symptoms and medication in German patients with rheumatoid arthritis-results from the linking patient-reported outcomes with claims data for health services research in rheumatology (PROCLAIR) study. Pharmacoepidemiol Drug Saf 26(7):766\u2013774. https:\/\/doi.org\/10.1002\/pds.4202","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"971_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00393-019-0650-7","volume":"78","author":"H Haibel","year":"2019","unstructured":"Haibel\u00a0H, Redeker\u00a0I, Zink\u00a0A, Callhoff\u00a0J, Marschall\u00a0U, Hoffmann\u00a0F, Sieper\u00a0J, Poddubnyy\u00a0D (2019) Health care and disease burden in persons with axial spondyloarthritis in Germany. Z\u00a0Rheumatol 78(9):865\u2013874. https:\/\/doi.org\/10.1007\/s00393-019-0650-7","journal-title":"Z Rheumatol"},{"issue":"7","key":"971_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/annrheumdis-2017-212629","volume":"77","author":"I Redeker","year":"2018","unstructured":"Redeker\u00a0I, Hoffmann\u00a0F, Callhoff\u00a0J, Haibel\u00a0H, Sieper\u00a0J, Zink\u00a0A, Poddubnyy\u00a0D (2018) Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Ann Rheum Dis 77(7):1017\u20131024. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212629","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"971_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00393-019-0680-1","volume":"78","author":"K Albrecht","year":"2019","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Zink\u00a0A (2019) Long-term trends in rheumatology care : achievements and deficits in 25\u00a0years of the German national rheumatology database. Z\u00a0Rheumatol 78(2):65\u201372. https:\/\/doi.org\/10.1007\/s00393-019-0680-1","journal-title":"Z Rheumatol"},{"issue":"1","key":"971_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00393-019-0678-8","volume":"79","author":"I Redeker","year":"2020","unstructured":"Redeker\u00a0I, Callhoff\u00a0J, Hoffmann\u00a0F, Saam\u00a0J, Haibel\u00a0H, Sieper\u00a0J, Zink\u00a0A, Poddubnyy\u00a0D (2020) Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a\u00a0routine data analysis. Z\u00a0Rheumatol 79(1):85\u201394. https:\/\/doi.org\/10.1007\/s00393-019-0678-8","journal-title":"Z Rheumatol"},{"key":"971_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2020.1762923","author":"K Rebane","year":"2020","unstructured":"Rebane\u00a0K, Aalto\u00a0K, Haanpaa\u00a0M, Puolakka\u00a0K, Virta\u00a0LJ, Kautiainen\u00a0H, Pohjankoski\u00a0H (2020) Initiating disease-modifying anti-rheumatic drugs rapidly reduces purchases of analgesic drugs in juvenile idiopathic arthritis. Scand J Rheumatol. https:\/\/doi.org\/10.1080\/03009742.2020.1762923","journal-title":"Scand J Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00971-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-00971-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00971-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T09:04:46Z","timestamp":1641891886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-00971-y"}},"subtitle":["A\u00a0claims data analysis","Eine Analyse von Abrechnungsdaten. Englische Version"],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":32,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-00971-y","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"12 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.\u00a0Albrecht, U.\u00a0Marschall and J.\u00a0Callhoff declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}